Jan 22, 2013 by Max Macaluso and Dave WilliamsonDoes This Big Pharma Have an Edge?How can Sanofi continue to grow?
Jan 22, 2013 by Max Macaluso and Dave WilliamsonWhat's Behind the Curtain at Eli Lilly?Eli Lilly's open innovation initiatives could work in the long run.
Jan 22, 2013 by Max Macaluso and Brenton FlynnCan Impax Labs Shrug Off This Rejection?FDA rejection for Impax's Parkinson's disease drug.
Jan 22, 2013 by Max Macaluso and Brenton FlynnWhy Arena Got Crushed TodayWith Belviq's US launch just around the corner, investors wonder if this drug will ever be marketed in Europe.
Jan 22, 2013 by Max Macaluso and Brenton FlynnNew Hope for Celsion Investors?This agreement adds more suspense as investors await Phase 3 clinical trial results from Celsion.
Jan 19, 2013 by Max MacalusoCan Glaxo Show Its Worth in 2013?Is GlaxoSmithKiline's revolutionary R&D strategy going to work?
Jan 19, 2013 by Max MacalusoIs This the Start of an AstraZeneca Revolution?Is the transformation complete, or does this drugmaker still have a lot of work ahead?
Jan 18, 2013 by Max Macaluso and Dave WilliamsonBig Pharma Diabetes Face-OffAre there too many options in the GLP-1 market?
Jan 17, 2013 by Max MacalusoAsk a Fool: Is the Medical Community Prime for Shorting?Is the medical community a dangerous place to invest right now?
Jan 11, 2013 by Max Macaluso1 Problem This Pharma Doesn’t Want to Talk About What about the MS market?
Jan 11, 2013 by Max MacalusoCan This Biotech Wow Wall Street?Will Iclusig's drug launch be a success?
Jan 9, 2013 by Max MacalusoWill Sarepta Be Bought Out in 2013? Never say never, but it doesn't look likely.
Jan 9, 2013 by Max Macaluso1 Medical Device Player Not "Stryker-ing" OutWhat happened with Stryker today?
Jan 9, 2013 by Max Macaluso1 Medical Device Preview Investors Were Hoping ForGood news today at NuVasive.
Jan 9, 2013 by Max MacalusoDown 10%: Peregrine Hits the BrakesAfter a great run this week, it looks like Peregrine is taking a breather.
Jan 8, 2013 by Max MacalusoAnchors Aweigh For This BiotechIs This the Opportunity Amarin Investors Are Neglecting?
Jan 8, 2013 by Max MacalusoBiotech Grudge Match: Game, Set, & Match?Is it smooth sailing ahead for Affymax?
Jan 8, 2013 by Max Macaluso3 Ingredients for an Obesity Drug BlockbusterCan VIVUS's Qsymia Become a Billion Dollar Medication?
Jan 8, 2013 by Max MacalusoAmarin's Drug Launch: Mega Hit or Epic Fail?Will Vascepa be a hit in 2013?
Jan 7, 2013 by Max MacalusoWill VIVUS Prove Doubters Wrong? Impressive prescription data from VIVUS today - is this a bigger threat than Arena thought?
